Kazia Therapeutics Annual Report 2021

2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 53 EVT801 licensing agreement Paxalisib licensing agreement Total Consolidated $ $ $ Balance at 1 July 2019 - 13,494,483 13,494,483 Amortisation expense - (1,084,344) (1,084,344) Balance at 30 June 2020 - 12,410,139 12,410,139 Additions 10,857,763 - 10,857,763 Amortisation expense (180,965) (1,084,344) (1,265,309) Balance at 30 June 2021 10,676,798 11,325,795 22,002,593 During the financial year the consolidated entity acquired exclusive rights to EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). NOTE 13. TRADE AND OTHER PAYABLES Consolidated 2021 2020 $ $ Current liabilities Trade payables 1,893,150 1,693,632 Accrued payables 3,039,510 1,795,301 4,932,660 3,488,933 Refer to note 21 for further information on financial instruments. NOTE 14. EMPLOYEE BENEFITS Consolidated 2021 2020 $ $ Current liabilities Annual leave 229,337 191,451 Non-current liabilities Long service leave 54,684 - 284,021 191,451 NOTE 15. CONTINGENT CONSIDERATION Consolidated 2021 2020 $ $ Current liabilities Contingent consideration – paxalisib - 1,387,089 Contingent consideration - EVT801 3,164,557 - 3,164,557 1,387,089 Non-current liabilities Contingent consideration – paxalisib 1,015,249 457,899 Contingent consideration – EVT801 7,911,392 - 8,926,641 457,899 12,091,198 1,844,988 NOTE 12. INTANGIBLES (CONTINUED)